There are hundreds of early clinical trials, but only a handful of late-stage ones have reached completion.
The approach could be a tenth the price of earlier methods.
The medical maker collective Four Thieves Vinegar made an “EpiPencil” for a tiny fraction of what the EpiPen manufacturer Mylan charges.
Mapping the 3-D network structure of a fly’s brain is a major step forward. But it took 1,700 person-hours to complete, meaning that human labor will be a significant bottleneck for future advances.
For patients with some inherited diseases, a chance to test an experimental treatment can offer the only hope.
Can cell therapy help spinal-cord injury? A long-running study hopes the answer is yes.
But the technology for extinguishing species is dividing conservationists.
The blood-testing startup adds a flubbed test for the Zika virus to its rap sheet.
An antibody that clears up brain-destroying plaques may settle the cause of Alzheimer’s once and for all.
A key theory of blood dynamics has been overturned by video evidence showing how red blood cells can make blood less viscous.